treatment
short
stature
children
adolescents
human
pituitary
growth
hormone
raben
experience
thirtyfive
cases
human
pituitary
growth
hormone
raben
evaluated
longitudinal
study
growth
a
therapeutic
agent
treatment
short
stature
clinically
significant
increases
growth
rate
achieved
hypopituitary
patients
significant
improvement
linear
growth
rate
noted
a
dose
mg
times
weekly
children
whose
short
stature
due
conditions
adverse
reactions
noted
thyroidal
adrenal
gonadal
activation
observed
growth
stimulated
probably
without
undue
increase
bone
age
though
point
demands
continued
scrutiny
owing
limited
supply
material
recommended
used
cases
documented
growth
failure
a
protocol
evaluation
therapeutic
response
discussed
though
a
panacea
treatment
short
stature
human
growth
hormone
fulfils
a
unique
invaluable
role
replacement
therapy
hypopituitary
dwarf
